Journal of the National Cancer Institute Advance Access originally published online on April 29, 2008
JNCI Journal of the National Cancer Institute 2008 100(9):680-681; doi:10.1093/jnci/djn108
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2008. Published by Oxford University Press.
CORRESPONDENCE |
Response:Re: HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials
Affiliations of authors: Department of Clinical Epidemiology and Medical Oncology, National Cancer Research Institute, Genoa, Italy (AG, PP, PB); Department of Health Sciences, University of Genoa, Italy (AG, MPS)
Correspondence to: Alessandra Gennari, MD, PhD, National Cancer Research Institute, Largo Rosanna Benzi, 10 16132 Genoa, Italy (e-mail: alessandra.gennari@istge.it).
| The first 10% of the full text of this article appears below. |
Dr Mehta correctly points out that there may be subgroups of HER2-negative patients who would benefit from the use of anthracycline-containing adjuvant chemotherapy, and she suggests that some anthracycline-containing regimens (especially the
Related Correspondence
![]()
CiteULike
Connotea
Del.icio.us What's this?
J Natl Cancer Inst 2008 100: 680.